TIDMSUN
RNS Number : 1108A
Surgical Innovations Group PLC
22 May 2023
Surgical Innovations Group Plc
(the "Company")
Directorate changes and board succession planning
Surgical Innovations Group Plc (AIM: SUN), the designer,
manufacturer and distributor of innovative technology for minimally
invasive surgery, announces the appointment of Jonathan Glenn as
Senior Independent Non-executive Director and Chairman-designate of
the Company with immediate effect.
Jonathan is an experienced board director and chairman, with an
excellent track record in the medical device sector. He is
currently Non-executive Chairman of Tissue Regenix plc, and was
formerly Group CEO of Consort Medical Plc from 2007 to 2020, where
he oversaw the GBP230m acquisition of a European contract
development and manufacturing organisation. Jonathan led the
business as CEO until its acquisition for GBP505m in 2020. Jonathan
is a member of the Institute of Chartered Accountants in England
and Wales.
He joins the board in anticipation of the upcoming retirement of
Professor Mike McMahon, the founder of the Company, who retires
from the board at the Annual General Meeting of the Company
expected to take place on 27 June 2023.
Following an orderly handover process, Jonathan will succeed
Nigel Rogers as Chairman upon announcement of the interim results
expected in September 2023. Nigel has indicated his intention to
remain on the board until an additional independent non-executive
director has been appointed.
Chairman of the Company, Nigel Rogers, commented: "It has been
my great pleasure to lead the board since my appointment in 2015,
and especially to work alongside Prof. Mike McMahon. As part of our
planned succession arrangements, we are now delighted to have
Jonathan joining us, and look forward to working with him to
complete the transition in board composition for the next stage in
the Company's evolution."
A separate announcement will be made in due course giving formal
notice of the Company's 2023 AGM.
The following information is disclosed pursuant to Rule 17 and
Schedule Two paragraph (g) of the AIM Rules for Companies:
Jonathan Martin Glenn (aged 54 ) is currently, or has during the
past five years, been a director of the following companies:
Current directorships or partnerships Previous directorships or partnerships
* Tissue Regenix Group plc * AESICA BC Limited
* Tissue Regenix Holdings Limited * AESICA Formulation Development Limited
* TRX Cardiac Limited * AESICA Holdco Limited
* TRX Orthopaedics Limited * AESICA M1 Limited
* TRX Vascular Limited * AESICA M2 Limited
* TRX Wound Care Limited * AESICA Queensborough Limited
* Tissue Regenix Limited * AESICA Trustee Company Limited
* Tissue Regenix Holdings Inc * Bespak Europe Limited
* Tissue Regenix Wound Care Inc * Bespak Finance Limited
* TRX Orthopedics Inc * Bespak Holdings Limited
* Binx Health Limited
* Consort Medical Finance 2010 Limited
* Consort Medical Finance Limited
* Consort Medical Limited
* Consort Medical plc
* Integrated Aluminium Components Limited
* Medical House (ASI) Limited
* Medical House Products Limited
* Pharmaron Manufacturing Services (UK) Ltd
* The Medical House Group Limited
* The Medical House Limited
------------------------------------------------------
Save as set out in this announcement there are no further
details to be disclosed in accordance with Rule 17 and Schedule Two
Paragraph (g) of the AIM Rule for Companies.
For further information please contact:
Surgical Innovations Group plc www sigroupplc com
David Marsh, CEO Tel: 0113 230 7597
Charmaine Day, CFO
Singer Capital Markets (Nominated Tel: 020 7496 3000
Adviser & Broker)
Aubrey Powell / Oliver Platts
Walbrook PR (Financial PR & Investor Tel: 020 7933 8780 or si@walbrookpr.com
Relations)
Paul McManus / Lianne Applegarth Mob: 07980 541 893 / 07584
391 303
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and
distribution of innovative, high quality medical products,
primarily for use in minimally invasive surgery. Our product and
business development is guided and supported by a key group of
nationally and internationally renowned surgeons across the
spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access
systems, surgical instruments and retraction devices which are sold
directly in the UK home market through our subsidiary, Elemental
Healthcare, and exported widely through a global network of trusted
distribution partners. Many of our products in this field are based
on a "resposable" concept, in which the products are part reusable,
part disposable, offering a high quality and environmentally
responsible solution at a cost that is competitive against fully
disposable alternatives.
Elemental also has exclusive UK distribution for a select group
of specialist products employed in laparoscopy, bariatric and
metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully
selected OEM partners and have also collaborated with a major UK
industrial partner to provide precision engineering solutions to
complex problems outside the medical arena.
We aim for our brands to be recognised and respected by
healthcare professionals in all major geographical markets in which
we operate and provide by development, partnership or acquisition a
broad portfolio of cost effective, procedure specific surgical
instruments and implantable devices that offer reliable solutions
to genuine clinical needs in the operating theatre environment.
Further information
Further details of the Group's businesses and products are
available on the following websites:
www.sigroupplc.com
www.surginno.com
www.elementalhealthcare.co.uk
To receive regular updates by email, please contact
si@walbrookpr.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEASSFASEDEFA
(END) Dow Jones Newswires
May 22, 2023 02:00 ET (06:00 GMT)
Surgical Innovations (LSE:SUN)
Historical Stock Chart
From Jan 2025 to Feb 2025
Surgical Innovations (LSE:SUN)
Historical Stock Chart
From Feb 2024 to Feb 2025
